Browse the evidence

GLP-1 receptor agonists reduce cardiovascular risk (MACE) and improve renal outcomes in patients with Type 2 Diabetes, independent of weight loss.

For patients with Type 2 Diabetes, especially those with heart disease or kidney risks, GLP-1 medications offer significant protection against heart attacks, strokes, and kidney failure. These benefits are independent of weight loss and are supported by extensive clinical trial data. The choice between daily injections, weekly injections, or oral tablets depends on patient preference and tolerance.

Bariatric surgery (e.g., Roux-en-Y gastric bypass, sleeve gastrectomy) is an effective treatment for obesity and T2DM, capable of inducing remission of diabetes through both weight-loss-dependent and weight-loss-independent mechanisms.

Bariatric surgery is a powerful tool for treating obesity and Type 2 Diabetes. It can lead to diabetes remission (normal blood sugar without meds) through both weight loss and hormonal changes. It is invasive and carries risks like nutrient deficiencies, so it requires lifelong medical monitoring.

Metformin provides modest weight loss (average ~2.1 kg/year) and improves insulin sensitivity, making it a first-line treatment for T2DM, though it is not FDA-approved specifically for weight loss.

Metformin is a standard first-line medication for Type 2 Diabetes. It helps control blood sugar and may lead to modest weight loss (about 2 kg per year), but it is not a powerful weight-loss drug. It is generally safe and well-tolerated, though some people experience gastrointestinal side effects.

The physical function benefits of long-term intensive lifestyle intervention are more pronounced in older adults (≥60 years) compared to younger adults (<60 years).

If you are over 60, the mobility benefits of lifestyle changes may be even more valuable to you than for younger people, as the intervention had a larger effect on physical function scores in this age group.

GLP-1 receptor agonists (e.g., semaglutide) and GLP-2 analogs (e.g., teduglutide) are FDA-approved interventions that treat obesity and short bowel syndrome by mimicking enteroendocrine cell hormone secretion.

If you have obesity or short bowel syndrome, talk to your doctor about GLP-1 based medications like semaglutide. These are FDA-approved treatments that mimic your gut's natural hormones to help with weight loss or nutrient absorption. They are not lifestyle fixes but medical interventions for specific conditions.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) provide cardiovascular and kidney protection in patients with chronic kidney disease (CKD) and overweight/obesity, with or without type 2 diabetes (T2DM), by reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression.

If you have chronic kidney disease and are overweight or obese, ask your doctor about GLP-1 receptor agonists like semaglutide or liraglutide. These medications are not just for weight loss; they have been proven to protect your heart and kidneys, even if you do not have diabetes. They are available in both daily and weekly formulations, and sometimes orally, making them a versatile option for managing your overall metabolic health.

Liraglutide 1.8 mg/day reduces the risk of major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality in patients with Type 2 Diabetes and high cardiovascular risk.

If you have Type 2 Diabetes and are at high risk for heart problems, adding a daily 1.8 mg liraglutide injection can significantly lower your risk of heart attack, stroke, and death from cardiovascular causes, without increasing the risk of heart failure hospitalization.

Semaglutide (2.4 mg weekly) produces a clinically significant reduction in systolic blood pressure (approx. 4.8 mmHg) and diastolic blood pressure (approx. 2.5 mmHg) in adults with obesity but without diabetes, even among those with normotensive baseline blood pressure.

If you have obesity and high blood pressure (or even normal blood pressure), semaglutide 2.4 mg taken once weekly can significantly lower your blood pressure. This benefit exists even if you are not currently diagnosed with hypertension. It is a weight-centric approach to managing blood pressure.

Insulin therapy is associated with significant weight gain (mean 4.3 kg) in patients with Type 2 Diabetes, driven by caloric conservation, anabolic effects, and defensive eating to avoid hypoglycemia.

If you are on insulin and gaining weight, know that this is a known side effect caused by how insulin stores energy and your body's response to prevent low blood sugar. Discuss switching to or adding GLP-1 agonists with your doctor, as they can help with weight loss while managing blood sugar.

A 12-week treatment with dulaglutide prevents post-cessation weight gain in the short term (12 weeks), but this benefit is lost after discontinuation, resulting in similar weight gain to placebo at 52 weeks.

Dulaglutide can help you avoid gaining weight during your first 12 weeks of quitting smoking. However, once you stop the injections, you will likely gain weight similar to someone not taking the drug. To maintain weight loss, you may need to stay on the medication longer than 12 weeks.

Interval training (IT) and moderate intensity continuous training (MICT) produce equivalent changes in whole-body fat mass and fat-free mass over time.

If your goal is to change your body composition (lose fat or gain muscle), it does not matter whether you choose high-intensity interval training (HIIT) or moderate-intensity continuous training (MICT). Both approaches yield similar results. Focus on choosing the type of exercise you enjoy and can stick with consistently, as adherence is likely more important than the specific intensity profile for long-term body composition changes.

GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), including cardiovascular mortality, myocardial infarction, and stroke, in patients with type 2 diabetes and high cardiovascular risk.

If you have Type 2 Diabetes and existing heart disease or high risk, GLP-1 receptor agonists (like Semaglutide or Liraglutide) are proven to lower your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of weight loss in some cases, though weight loss often accompanies it. Discuss these options with your doctor, especially if you are at high risk.

Consuming processed meat increases the risk of colorectal cancer, with each 50-gram daily increase linked to an 18% higher risk.

To reduce colorectal cancer risk, limit processed meat intake (bacon, sausage, hot dogs, lunch meats). Each 50g daily increase raises risk by 18%. Be aware that 'nitrite-free' labels often use celery juice, which acts as a nitrate source and carries similar risks. Focus on reducing overall processed meat consumption rather than seeking 'safer' processed alternatives.

An intensive lifestyle intervention (ILI) combining caloric restriction, structured meal replacements, and increased physical activity produces significant initial weight loss and modest long-term maintenance in adults with type 2 diabetes, but does not reduce cardiovascular morbidity or mortality compared to standard education.

For adults with type 2 diabetes, an intensive lifestyle program focusing on moderate caloric restriction (1200-1800 kcal), structured meal replacements (initially 2 meals/day), and 175 minutes of weekly moderate activity can achieve significant weight loss and improve metabolic markers like A1C and lipids. However, do not prioritize weight loss over glucose management or quality of life. Expect some weight regain after the first year, but maintain the focus on behavioral adherence and metabolic health, as initial losses provide long-term benefits even if full maintenance is difficult.

Treatment with GLP-1 RAs or GIP/GLP-1 RAs significantly reduces the risk of myocardial infarction (MI) and nonfatal MI in overweight or obese adults without diabetes, but does not significantly reduce the risk of stroke.

In non-diabetic overweight or obese adults, GLP-1 and GIP/GLP-1 receptor agonists significantly lower the risk of heart attacks (myocardial infarction), including nonfatal ones. However, these drugs did not show a significant reduction in stroke risk in this specific population, unlike some findings in diabetic patients.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) by approximately 14% in patients with type 2 diabetes, independent of glucose-lowering effects.

If you have Type 2 Diabetes and are at risk for heart disease, GLP-1 medications (like semaglutide or liraglutide) are proven to significantly lower your risk of heart attack, stroke, and cardiovascular death. These benefits exist even beyond just lowering blood sugar. While injections can cause stomach upset, starting with a low dose and increasing slowly usually manages this. Oral options are also available for some drugs.

GLP-1 receptor agonists significantly reduce the risk of major adverse cardiovascular events (MACE), cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure in both patients with type 2 diabetes and overweight/obese patients without diabetes.

If you have type 2 diabetes or are overweight/obese with cardiovascular risk factors, GLP-1 receptor agonists (like semaglutide or liraglutide) can significantly lower your risk of heart attacks, strokes, and heart failure hospitalizations, regardless of whether you have diabetes. These benefits are seen with both daily and weekly formulations, and oral options exist.

Weight loss of >10% body weight is required to resolve NASH and regress fibrosis, but this is rarely achieved in routine clinical settings.

Aim for >10% weight loss to potentially reverse NASH and fibrosis, but recognize this is difficult. If you cannot achieve this, focus on a Mediterranean diet to improve liver health and insulin sensitivity even without significant weight loss.

Visceral Adipose Tissue (VAT) and ectopic fat deposition are causal drivers of cardiometabolic disease, whereas subcutaneous fat (specifically gluteofemoral adipose tissue, GFAT) is protective, independent of total body weight.

Focus on preserving subcutaneous fat storage capacity (especially in hips/thighs) and reducing visceral/abdominal fat. This is achieved through diet quality and physical activity, not just weight loss. If you have a 'skinny fat' phenotype (normal weight but high visceral fat), your risk is high. If you have a 'healthy obese' phenotype (high weight but low visceral fat and good metabolism), your risk may be lower than expected.

GLP-1 receptor agonists (semaglutide, tirzepatide) induce high rates of reversion to normoglycemia in individuals with prediabetes, but these benefits are largely lost upon discontinuation of the therapy.

GLP-1 medications like semaglutide are highly effective at reversing prediabetes, with nearly all users returning to normal blood sugar levels while taking the drug. However, stopping the medication usually leads to weight regain and the return of prediabetes. Discuss with your doctor whether this is a short-term reset or a long-term management strategy for you.

Semaglutide 2.4 mg weekly reduces major adverse cardiovascular events (MACE) by 20% in people with BMI ≥27 kg/m² and pre-existing cardiovascular disease, independent of diabetes status.

If you are overweight (BMI 27+) and have heart disease, ask your doctor about semaglutide. It has been shown to reduce the risk of heart attack, stroke, or death from heart causes by 20%. This benefit exists even if you don't have diabetes.

The IWQOL-Lite-CT is a validated patient-reported outcome measure that accurately detects clinically meaningful improvements in physical and psychosocial functioning in patients with overweight or obesity undergoing weight management interventions.

Use the IWQOL-Lite-CT to track how weight loss interventions impact patients' daily physical and psychosocial functioning. It is a validated, 20-item questionnaire that provides a comprehensive assessment of treatment benefit from the patient's perspective, suitable for clinical trials and potentially clinical practice to gauge meaningful within-patient change.

Intentional weight loss triggers strong counterregulatory physiological responses, specifically increased hunger and reduced energy expenditure (hypometabolism), which actively defend the original body weight and facilitate rapid weight regain.

Expect that losing weight will make you hungrier and your metabolism slower. This is a biological defense, not a personal failure. To maintain loss, you must actively counterbalance these adaptations, likely through strategies like increased physical activity and specific dietary choices (e.g., fiber) that support metabolic rate, as standard willpower-based approaches often fail against this biological pushback.

Lifestyle interventions (diet/exercise) are the cornerstone of obesity treatment but are rarely sufficient for long-term weight maintenance due to metabolic adaptations.

Lose weight through diet and exercise, but expect your body to fight back. Your metabolism will slow down, and hunger hormones will rise. To keep the weight off, you likely need medical support (medication or surgery) in addition to lifestyle changes.